|
KDPharm is a pharmaceutical company established in 1976 that manufactures and sells prescription and over-the-counter medicines, active pharmaceutical ingredients, and health supplements. The company's primary business segment is pharmaceuticals, which accounts for the majority of its revenue, with additional income from real estate leasing and other products. Key products include Duo Lovan tablets, Alpotin soft capsules, Durofin sustained-release tablets, and the WIAVIM health supplement brand. KDPharm serves the domestic market through hospitals, clinics, and pharmacies, with a small portion of sales exported via pharmaceutical trading companies. The company operates GMP-compliant manufacturing facilities and focuses on developing improved new drugs, generics, and complex formulations for cardiovascular, digestive, and respiratory conditions. It also engages in research and development for active ingredients such as risperidone and pitavastatin calcium hydrate, and has signed joint research agreements with partners like Incelibro. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage kdpharma.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
prescription drugs, over-the-counter drugs, active pharmaceutical ingredients, health supplements, cardiovascular drugs, digestive drugs, respiratory drugs, complex formulations, generics, improved new drugs, Duo Lovan, Alpotin, Durofin, Euro nal, Valtrio, Dapamet, WIAVIM, Kotuluten, Anico In Hot & Cool Plaster, Incilibro
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 152.305B |
| P/E | 5.95 |
| P/BV | 0.66 |
| P/S | 0.76 |
| P/OCF | 7.37 |
| P/FCF | 33.07 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 3.8% |
| ROI | 3.7% |
| ROIC | 3.1% |
| Profit margin | 4.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 17.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 196.273B | 193.936B | 162.674B | 182.718B | 177.611B | 173.828B | 176.5B | 179.316B | 177.772B | 158.599B | 151.893B | 153.26B | 133.074B |
| Free cash flow | -1.46B | -15.692B | -6.322B | -11.649B | 8.496B | -11.475B | -4.836B | 29.337B | 9.044B | 18.433B | 7.57B | 1.958B | 7.041B |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.